Coombes Brandon J, Sanchez-Ruiz Jorge A, Fennessy Brian, Pazdernik Vanessa K, Adekkanattu Prakash, Nuñez Nicolas A, Lepow Lauren, Melhuish Beaupre Lindsay M, Ryu Euijung, Talati Ardesheer, Mann J John, Weissman Myrna M, Olfson Mark, Pathak Jyotishman, Charney Alexander W, Biernacka Joanna M
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Psychiatry Res. 2024 Dec;342:116203. doi: 10.1016/j.psychres.2024.116203. Epub 2024 Sep 16.
Treatment resistance is common in major depressive disorder (MDD), yet clinical risk factors are not well understood. Using a discovery-replication design, we conducted phenome-wide association studies (PheWASs) of MDD treatment resistance in two electronic health record (EHR)-linked biobanks. The PheWAS included participants with an MDD diagnosis in the EHR and at least one antidepressant (AD) prescription. Participant lifetime diagnoses were mapped to phecodes. PheWASs were conducted for three treatment resistance outcomes based on AD prescription data: number of unique ADs prescribed, ≥1 and ≥2 CE switches. Of the 180 phecodes significantly associated with these outcomes in the discovery cohort (n = 12,558), 71 replicated (n = 8,206). In addition to identifying known clinical factors for treatment resistance in MDD, the total unique AD prescriptions was associated with additional clinical variables including irritable bowel syndrome, gastroesophageal reflux disease, symptomatic menopause, and spondylosis. We calculated polygenic risk of specific-associated conditions and tested their association with AD outcomes revealing that genetic risk for many of these conditions is also associated with the total unique AD prescriptions. The number of unique ADs prescribed, which is easily assessed in EHRs, provides a more nuanced measure of treatment resistance, and may facilitate future research and clinical application in this area.
治疗抵抗在重度抑郁症(MDD)中很常见,但临床风险因素尚未得到很好的理解。我们采用发现-重复设计,在两个与电子健康记录(EHR)相关联的生物样本库中对MDD治疗抵抗进行了全表型关联研究(PheWASs)。该PheWAS纳入了在EHR中有MDD诊断且至少有一次抗抑郁药(AD)处方记录的参与者。参与者的终生诊断结果被映射到疾病编码。基于AD处方数据,针对三个治疗抵抗结果进行了PheWASs分析:所开具的不同AD的数量、≥1次和≥2次的换用其他抗抑郁药情况。在发现队列(n = 12,558)中,有180个疾病编码与这些结果显著相关,其中71个在重复队列(n = 8,206)中得到重复验证。除了确定MDD治疗抵抗的已知临床因素外,总的不同AD处方数量还与其他临床变量相关,包括肠易激综合征、胃食管反流病、症状性更年期和脊椎病。我们计算了特定相关疾病的多基因风险,并测试了它们与AD治疗结果的关联,结果显示许多这些疾病的遗传风险也与总的不同AD处方数量相关。所开具的不同AD的数量在EHR中易于评估,它提供了一种更细致的治疗抵抗衡量方法,可能会促进该领域未来的研究和临床应用。